The effect of valsartan, an angiotensin II receptor antagonist, on portal and systemic hemodynamics and on renal function in liver cirrhosis.
OBJECTIVE
The aim of the study was to assess the effects of valsartan, a new generation angiotensin II receptor antagonist, on portal and systemic hemodynamics and on renal function in cirrhosis.


METHODS
Eighty patients with cirrhosis and portal hypertension were divided in two groups as follows: group I - 40 patients who received valsartan (Diovan) 80 mg /day for 7 days and group II - 40 patients who received placebo. All the patients had hemodynamic, endocrine and renal parameters measured on day 0 and 7. The following were assessed: creatinine clearance, lithium clearance, plasma renin activity, concentration of plasma aldosteron and sodium homeostasis. Hemodynamic effects were assessed sonographically by portal flow volume and velocity evaluation, and mean arterial blood pressure.


RESULTS
Valsartan increased the portal blood flow and the portal velocity (p < 0.01). These changes occurred without any significant changes in blood pressure and renal function or the glomerular filtration rate, compared with controls (p > 0.05). Valsartan also reduced the concentration of plasma aldosteron (p < 0.01) and increased the urinary sodium excretion (p < 0.001).


CONCLUSIONS
A one week treatment with valsartan in cirrhotic patients with portal hypertension determines an increase in natriuresis, which could be regarded as beneficial and changes in the portal hemodynamics which might be speculated to represent a reduction of portal resistance.
Fierbinteanu-Braticevici
Carmen
C
2nd Medical Clinic-Gastroenterology, University Hospital, Splaiul Independentei no. 169, Bucharest, Romania. cfierbinteanu@yahoo.com
Dragomir
Paul
P
Tribus
Laura
L
Negreanu
Lucian
L
Bengus
Andreea
A
Usvat
Radu
R
Andronescu
Dan
D
D000328:Adult; D000368:Aged; D000450:Aldosterone / Q000097:blood; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood / Q000652:urine; D003404:Creatinine / Q000097:blood; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006975:Hypertension, Portal / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D007668:Kidney / Q000187:drug effects* / Q000503:physiopathology; D008103:Liver Cirrhosis / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D008676:Metanephrine / Q000652:urine; D008875:Middle Aged; D009318:Natriuresis / Q000187:drug effects; D011168:Portal System / Q000187:drug effects* / Q000503:physiopathology; D012083:Renin / Q000097:blood; D012383:Romania; D016037:Single-Blind Method; D012964:Sodium / Q000652:urine; D013777:Tetrazoles / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D014633:Valine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000068756:Valsartan
D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D015415:Biomarkers; D013777:Tetrazoles; D000450:Aldosterone; D008676:Metanephrine; D000068756:Valsartan; D012964:Sodium; D003404:Creatinine; D012083:Renin; D014633:Valine